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Abstract
Multiple epidemiological studies have demonstrated associations between the human leukocyte antigen (HLA) loci and human immunodeﬁciency virus (HIV) disease, and more recently the killer cell
immunoglobulin-like (KIR) locus has been implicated in differential
responses to the virus. Genome-wide association studies have convincingly shown that the HLA class I locus is the most signiﬁcant host genetic
contributor to the variation in HIV control, underscoring a central role
for CD8 T cells in resistance to the virus. However, both genetic and
functional data indicate that part of the HLA effect on HIV is due to
interactions between KIR and HLA genes, also implicating natural killer
cells in defense against viral infection and viral expansion prior to initiation of an adaptive response. We review the HLA and KIR associations
with HIV disease and the progress that has been made in understanding
the mechanisms that explain these associations.

This article is a U.S. government work, and is not subject to copyright in the United States.
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INTRODUCTION
HLA: human
leukocyte antigen
KIR: killer cell
immunoglobulin-like
receptor
HIV: human
immunodeﬁciency
virus
GWAS: genome-wide
association study
SIV: simian
immunodeﬁciency
virus
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The human leukocyte antigen (HLA) and killer
cell immunoglobulin-like (KIR) molecules are
encoded by two of the most diverse gene families in the human genome. Given the involvement of these molecules in fundamental immune processes such as antigen presentation to
T cells and regulation of natural killer (NK)
cell responses, it is no surprise that the extreme
diversity characterizing the HLA and KIR loci
impacts viral pathogenesis differentially across
individuals. HIV is now the most thoroughly
studied virus across many disciplines, including
viral/host immunogenetic relationships. As was
suspected based on earlier studies, the central
importance of the HLA class I locus in the differential control of HIV that is seen across patients was borne out in the ﬁrst genome-wide
association studies (GWAS), underscoring the
exclusive role of this locus in the whole genome
context.
HIV remains a global health problem,
with more than 30 million people infected
worldwide, concentrated most severely in subSaharan Africa. Nearly three decades of intensive research have now led to substantial
progress in understanding HIV pathogenesis
and immunity to the virus. The availability of
a model exploiting simian immunodeﬁciency
virus (SIV) in nonhuman primates has advanced
the ﬁeld. Improved access to antiretroviral therapy (ART) has decreased mortality and morbidity of HIV infection within those countries
where the drugs are available. However, HIV
vaccine development remains extremely challenging, with no clear success in humans.
The diversity of clinical outcomes after HIV
infection is broad, ranging from progression to
acquired immunodeﬁciency syndrome (AIDS)
within a year of seroconversion to the control of
HIV without drugs for more than two decades.
A small fraction of individuals are resistant to
HIV infection, even upon repeated exposure.
The diversity of responses to HIV has to do
with viral, host, and environmental variability,
all of which must eventually be meshed to generate a predictive algorithm for outcome after
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HIV exposure. There is now abundant information regarding host genetic variation and its
consequence on outcome to HIV infection, particularly at the HLA class I loci and, to a lesser
extent, the KIR locus. In this review, we focus
on HLA and KIR involvement in HIV/AIDS as
a model for viral diseases in general, summarizing the inﬂuence that variation at these loci has
on HIV-1 pathogenesis.

OVERVIEW OF HLA AND KIR
GENETICS AND FUNCTIONS
HLA class I and class II molecules present antigenic peptides on the surface of cells to CD8
and CD4 T cells, respectively. CD8 T cells kill
infected cells through recognition of viral epitopes or self stress peptides (i.e., intracellularly
derived peptides) presented in the context of
HLA class I on the target cell surface. CD4 T
cells recognize antigens that are primarily extracellularly derived and in the context of HLA
class II, resulting in production of cytokines that
help other immune cells to respond. Besides directing CD8 T cell activity, class I molecules
also regulate NK cell activity via interactions
with NK cell receptors, including KIRs.
The HLA class I and class II molecules are
encoded by genes located within the human major histocompatibility complex (MHC), which
encompasses ∼4 Mb on chromosome 6p21.3
(Figure 1). It is one of the most gene-dense regions within the human genome, containing 45
HLA-like genes and 208 non-HLA genes (1).
The HLA-like genes share both sequence and
structural homology, and many have immunological functions. The HLA class I region contains three classical class I genes (HLA-A, -B,
and -C) that are expressed by all nucleated cells
and encode transplantation antigens (2). The
classical class II genes are HLA-DP, -DQ, and
-DR, and their products are expressed on the
surface of antigen-presenting cells and B cells.
The deﬁning feature of HLA class I and class
II genes is their extreme polymorphism. Variation across HLA alleles is concentrated within
the regions encoding sites that bind peptides
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Figure 1
The genetic map of the human MHC. A subset of genes within the 4 Mb region of the MHC is shown. Numbers of alleles for the
classical class I and class II genes (based on the information from the IMGT/HLA database, http://www.ebi.ac.uk/imgt/hla) are
depicted in red.

and the T cell receptor. HLA-B is the most diverse gene in the human genome, with 1,800
alleles described in the IMGT/HLA database
(http://www.ebi.ac.uk/imgt/hla). The current focus on HLA in terms of its effects on
disease susceptibility/pathogenesis is the variation in the coding regions of the genes. Evidence suggests that even a single amino acid
change can inﬂuence structural and functional
properties of HLA antigens and can inﬂuence
susceptibility to HIV disease (3). Studies are
now beginning to focus on variants in noncoding regions of the HLA genes, which may affect the level of transcription, translation, and
splicing.
Extreme polymorphism of HLA genes parallels the diversity of the functionally related
KIR genes, which encode receptors that regulate NK cell function. NK cells are key mediators of innate immunity that kill aberrant target
cells or secrete cytokines without prior exposure to the target. NK cell activity is controlled
by a battery of inhibitory and activating receptors, most of which recognize HLA class I– or
class I–like molecules (4). KIRs are mainly expressed on CD56dim CD16pos NK cells, which
constitute the bulk of peripheral blood NK cells
and have high cytotoxic potential. Tolerance to
self can be generated through KIRs that inhibit
NK cell activity upon recognition of normal
levels of class I expression, whereas activation of
NK cells, potentially involving activating KIRs,
may occur when class I expression is downregulated. Extensive genetic polymorphism of the
KIR and HLA class I loci is likely to inﬂuence

variability in functional capacities of NK cells
across individuals.
KIR genes are arranged in a head-to-tail
cluster on human chromosome 19q13.4 spanning approximately 100–200 kb (5). KIR2DL
and KIR3DL genes encode molecules with
inhibitory capacity (with the exception of
KIR2DL4, which may have both inhibitory
and activation potential), whereas KIR2DS and
KIR3DS encode activating receptors. Substantial gene content and allelic variation are observed in humans (6). There are two basic
groups of KIR haplotypes, termed A and B
(Figure 2). Haplotype A consists of nine genes
and encodes predominantly inhibitory receptors, whereas the B haplotypes represent a
diverse group of haplotypes based on gene
content and contain more activating KIRs compared with haplotype A. Another speciﬁc feature of the KIR locus is that expression of KIR
genes is variegated and clonally restricted (7).
Multiple alleles exist for each KIR gene, and
alleles of a given KIR gene can vary in expression level or functional capacity. Despite a great
deal of variation in gene content across haplotypes, almost all individuals possess four framework genes: KIR3DL3, KIR3DP1, KIR2DL4,
and KIR3DL2. In addition, the vast majority
of humans possess loci encoding KIR2DL1,
KIR2DL2/2DL3, and KIR3DL1/3DS1. Inhibitory receptors encoded by these three loci
are probably the major players in KIR-mediated
NK cell recognition of HLA-B (KIR3DL1) and
HLA-C (KIR2DL1, KIR2DL2, KIR2DL3)
molecules on target cells.

www.annualreviews.org • HLA/KIR Restraint of HIV
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Figure 2
Schematic representation of two prototypic human KIR haplotypes. The digit before the letter D in the KIR gene name denotes the
number of Ig-like domains in the molecule, the letter following D speciﬁes long (L) or short (S) cytoplasmic tails in a corresponding
protein, or pseudogenes (P). Long tailed KIRs are inhibitory and short tailed are activating with the exception of KIR2DL4, which has
potential for both inhibition and activation. Gene pairs KIR2DL2/2DL3 and KIR3DL1/3DS1 are alleles of the same loci (shown in green
and orange). The four framework genes are shown as gray boxes. Genes encoding activating KIR with short tails and pseudogenes are
denoted by red and blue letters, respectively. The number of alleles differing at the amino acid level is shown above each gene (based on
data from the IPD-KIR database, http://www.ebi.ac.uk/ipd/kir).

HLA-B Bw4: a group
of HLA-B allotypes
with the serologically
deﬁned Bw4 motif at
amino acid positions
77–83 (Bw6 is the
alternative motif )
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Receptor-ligand relationships between
HLA and KIR are allotype speciﬁc. KIR3DL1
speciﬁcally recognizes HLA-B molecules
that have the serologically deﬁned Bw4
motif (amino acid positions 77–83), and
some KIR3DL1 subtypes exhibit a stronger
inhibitory effect in the presence of HLA-B
Bw4 subtypes that have isoleucine at position
80 (Bw4-80I) as opposed to threonine at the
same position (Bw4-80T) (8). Notably, the
KIR3DL1 gene has the highest number of alleles compared with other KIR genes (Figure 2),
and allotypes encoded by these alleles vary in
their level of expression and inhibitory capacity
(9–12).
Besides restraining NK cell cytotoxicity, inhibitory KIRs are also involved in developmental signaling. During the process of NK cell
education, or licensing, interactions between
inhibitory receptors and self class I molecules
are important for gaining functional potency to
eventually eliminate target cells with aberrant
MHC expression (13). Thus, inhibitory KIRs
essentially regulate NK cell function positively
and negatively.
Whereas inhibitory KIRs are relatively well
studied, the function of the activating KIRs remains somewhat obscure. The activating KIRs
have evolved from their inhibitory counterparts
in such a way that they bind HLA class I ligands with substantially lower afﬁnity despite
nearly identical sequences in their extracellular domains. No ligands have been identiﬁed
for KIR3DS1 to date despite its ∼97% protein
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sequence similarity to KIR3DL1 in the extracellular domain (8). It may be difﬁcult to reproduce some in vivo conditions that are essential
for binding of activating KIRs to their HLA
ligand, as the HLA molecule or even the KIR
itself may be altered in some way upon infection, allowing the interaction to take place. For
example, a speciﬁc viral or self stress peptide
bound to the class I molecule could potentially
convert the molecule from nonligand to ligand
status (14). Understanding speciﬁc features of
HLA and KIR allotypes as well as the nuances
of their interactions is critical in the assessment
of the HLA and KIR genetic impact on human
diseases.

HIV DISEASE COURSE AND ITS
VARIATION IN HUMANS
HIV infection starts with the eclipse phase,
which lasts several days before the virus reaches
draining lymph nodes and becomes detectable
in plasma (Figure 3). Subsequent rapid viral
replication in activated CD4 T cells and systemic spread lead to an exponential increase
in plasma viral load, which reaches its peak 3–
4 weeks after infection (15). By this time,
latent viral reservoirs are established, and
eradication of the virus becomes virtually
impossible.
Peak plasma viremia is followed by a
decrease to a relatively stable level called
“set point,” marking the end of the acute
phase of infection (Figure 3). The subsequent
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Figure 3
Dynamics of peripheral blood CD4 T cell counts and plasma viral load during a typical course of HIV
infection. The three major phases of infection are shown: acute, chronic, and AIDS. The eclipse phase is the
initial stage of the acute infection before systemic viral dissemination. The acute phase is characterized by
ﬂu-like symptoms and a peak viral load, followed by a drop to a set point level. During the asymptomatic
chronic phase, viral load gradually increases while CD4 T cell counts gradually decline to the level of 200
cells/ml of blood, a point deﬁning AIDS onset.

asymptomatic chronic phase can last for years,
during which viral load gradually increases and
CD4 T cell counts decrease to the point where
the immune system can no longer protect the
body from opportunistic infections or certain
cancers. Recent ﬁndings point to the importance of events within the gastrointestinal tract
for HIV/SIV pathogenesis (16). Massive depletion of CD4 T cells and structural damage occur in the gastrointestinal mucosa during the acute phase of HIV/SIV infection.
Increased mucosal permeability allows microbial translocation, which leads to chronic immune activation, the apparent driving force of
immunodeﬁciency.
A minority of HIV-1-infected individuals (∼5–15%) called long-term nonprogressors
(LTNP) maintain normal CD4 T cell counts
and remain AIDS-free in the absence of ART
(17). It is well established that the level of set
point viremia impacts disease progression (18,
19). Indeed, the vast majority of LTNP exhibit low-level viremia, some of them below 50
copies of the virus per ml of plasma. These elite

controllers (EC) have been invaluable in studies
of immunological correlates of virus control.

HLA AND KIR IN HIV IMMUNITY
HLA Class I and CD8 T Cells
The era of studies investigating HIV-speciﬁc
CD8 cytotoxic T lymphocytes (CTLs) from
the blood of infected patients began in the late
1980s (20–22), opening a ﬂoodgate of CTL
intelligence. CD8 T cell activity was shown
to temporarily correlate with initial control of
acute viremia (23, 24), and depletion of the CD8
T cells was linked to a loss of viral control in SIV
infection (25, 26). Many HLA class I–restricted
epitopes recognized by CD8 T cells were identiﬁed (http://www.hiv.lanl.gov) and characterized for their ability to cripple the virus (27–
30). Studies of HLA allelic effects on various
outcomes to HIV infection were published (see
following sections), and strong links between
speciﬁc viral mutations and a given HLA class I
allele were uncovered (31–33).
www.annualreviews.org • HLA/KIR Restraint of HIV

Long-term
nonprogressors
(LTNP): a minor
subset of HIV-infected
patients who do not
progress to AIDS in
the absence of drug
therapy
Elite controllers
(EC): a subset of
LTNP who maintain
their viral load below
the detection limit of
commercial assays (50
copies per ml of
plasma)
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Escape mutations:
mutations in the viral
sequences that arise
due to selective
pressure from the
immune response
Gag: an HIV
polyprotein precursor
that is cleaved into
four proteins, p17
matrix, p24 capsid, p7
nucleocapsid, and p6.
Gag p24 contains four
B∗ 57-restricted
immunodominant
epitopes, TW10,
KF11, IW9, QW9,
and a B∗ 27-restricted
immunodominant
epitope, KK10. An
abundance of Gag in
viral particles makes
this protein an
important antigen
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There is strong evidence that CD8 T cells
exert extreme selection pressure on HIV sequences over the course of infection (27, 34–
43), whether beneﬁcial to the host or not. Viral
escape mutations arising within the HLA class
I–restricted CD8 T cell epitopes can function
to disrupt binding of a viral peptide to HLA
class I or impair recognition by the T cell receptor. Mutation in regions immediately ﬂanking the epitope may affect antigen processing,
facilitating escape from CD8 T cell response
(44). About two-thirds of all nonenvelope viral mutations detected in the chronic phase are
attributed to CD8 T cell responses in HIV-1infected patients, indicating a dominant inﬂuence of this arm of immunity on viral evolution
(34). However, owing to apparent restrictions
on viral ﬁtness, the virus can afford only certain escape pathways, which can be predicted to
some extent by the patient’s HLA genotype (34,
45). Transmission of HIV containing a given
escape mutation to a new recipient may result in
reversion of the mutation, depending on the ﬁtness cost and the recipient’s immune response
(27, 46). Progress in sequencing technologies,
availability of large cohorts of HIV-1-infected
individuals, and new statistical tools have enabled detection of HIV-1 evolution driven by
CD8 T cell pressure at the population level (31–
33, 47, 48).
The dynamics of the CD8 T cell response
are complex, with signiﬁcant qualitative and
quantitative changes over the course of HIV
infection. Acute CD8 T cell responses typically target a small number of epitopes, and
responses to these speciﬁc epitopes rapidly decline after reaching a peak, which can be attributed to a decrease in viral load, viral escape,
and/or effector cell exhaustion (43, 49). During
the chronic phase of infection, immunodominance patterns generally change (50) and the
CD8 T cell response shifts to a broader epitope recognition pattern (51). Immunodominant CD8 T cell responses that make a larger
relative contribution to the total response developed during primary infection associate with
a lower viral set point, and preservation of these
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responses in the chronic phase associates with
slower CD4 decline (50).
Much effort has been directed toward identiﬁcation of unique features of HIV-speciﬁc CD8
T cell activity from LTNP and EC, in particular. Although the breadth and magnitude
of overall HIV-speciﬁc CD8 T cell responses
do not seem to correlate with HIV control in
chronically infected individuals (51, 52), CD8
responses directed against Gag were found to
be critical for viral suppression in chronic infection (51–56). This can be explained by the relatively conserved nature of this structural protein
and/or by the overall abundance of the Gag protein in virus particles that allows rapid processing and presentation of Gag peptides to CD8
T cells (57). In addition, HIV-speciﬁc CD8 T
cells from EC were more potent compared with
noncontrollers according to several parameters,
including the ability to produce multiple cytokines and chemokines, proliferate, and exert
cytotoxicity (58–63). Whether this is a cause
for or an effect of EC status requires further
consideration.

HLA Class II and CD4 T Cells
The key role of CD4 T cells in immune
responses is underscored by the devastating
consequences of CD4 T cell depletion in HIV
infection. Based on animal models of chronic
viral infections, investigators have suggested
that CD4 T cells are necessary for the maintenance of stable CD8 T cell memory, although
they are not essential in primary CD8 T cell responses (64–66). CD4 T cells are the principal
targets for HIV, and the virus preferentially infects HIV-speciﬁc CD4 T cells (67). Although
most HIV-speciﬁc CD4 T cells are not infected
(67) and may contribute to antiviral response,
there is an impairment in proliferative capacity
of these cells in viremic patients (68–70). In
contrast, preservation of virus-speciﬁc CD4
T cells that can proliferate and produce IL-2,
characteristic of central memory cells, is
associated with low viral load in both treated
and untreated patients (68–71). Besides the
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traditional helper function, virus-speciﬁc CD4
T cells can exert direct cytotoxicity against
HIV- and SIV-infected cells (72–74). In addition, induction of a virus-speciﬁc CD4 T cell
response has been documented in relatively
successful vaccinations against SIV (75) and
HIV (76).
Although HLA class II genetic associations
with HIV disease outcomes have been reported,
the ﬁndings are not nearly as convincing as
those for class I. This could be due to the outcomes tested, such as viral load, which largely
depends on class I–restricted CD8 responses.
In addition, HLA class II restriction is not as
well deﬁned as that for class I for several reasons: Class II epitopes are harder to pinpoint
because they vary in length to a greater extent
than do class I, class II tetramers are difﬁcult to
produce relative to class I tetramers, there are
lower frequencies of HIV-speciﬁc CD4 T cells
compared with CD8 T cells (77), and CD4 T
cells are depleted over the course of infection.
Alternatively, the promiscuity in antigen presentation across class II allotypes may render
alleles roughly equal in terms of HIV restriction, which results in the absence of clear genetic effects of class II variation (78, 79).
CD4 T cell responses have been systematically analyzed in chronically infected patients
to map epitopes across the clade B (78) and
clade C (80) viral proteomes. There was a signiﬁcant inverse correlation between the presence of the CD4 response to Gag and viral
load in untreated clade C patients (80). Recent
data using an expanded data set of the same cohort (80) indicated that individuals expressing
DRB1∗ 1303, an allele signiﬁcantly associated
with low viral load, have fewer Gag-speciﬁc responses compared with all other patients (B.
Julg, personal communication). These seemingly inconsistent results can probably be resolved by distinguishing cause from effect when
interpreting data that involve effector cell responses from HIV-infected patients.
The difﬁculties in studying CD4 T cell
responses in HIV infection in general may
explain the absence of any clear effect of
HLA class II polymorphism on HIV disease.

Alternatively, class II polymorphism may not
have any measurable effect on disease pathogenesis if would-be beneﬁcial responses conferred by certain alleles occur too late after
infection. Further attempts to deﬁne and distinguish CD4 T cell responses by comparisons
of their functions across individuals with distinct class II allotypes may be pivotal in the design of an effective vaccine where the protective
responses are generated prior to infection.

HLA Class I, KIR, and NK Cells
Similar to other viruses, HIV downregulates expression of class I molecules on the surface of
infected cells to escape from CD8 T cell lysis
(81). This renders the cells potential targets for
NK cells. Notably, HIV downregulates HLA-A
and HLA-B, whereas HLA-C expression is preserved (82). Thus, NK cell receptors that bind
HLA-C might be preferentially important in
recognition of infected cells.
Early HIV infection is characterized by expansion of blood NK cells, which precedes the
expansion of CD8 T cells (83). This expansion
can be inﬂuenced by a HLA class I genotype, as
investigators have shown that the frequencies of
NK cells expressing KIR3DS1 and, to a lesser
extent, KIR3DL1 are speciﬁcally increased during acute HIV-1 infection in the presence of
HLA-B Bw4-80I (84). Selected expansion of
NK cell subsets may be beneﬁcial to the host
because an immediate, aggressive response to
HIV may prevent an established infection.
Several studies have shown that NK cells
isolated from viremic patients are impaired in
their function (85–87). One reason for such impairment is the expansion of a CD56− CD16+
subset of NK cells that is present at low levels
in healthy individuals and in HIV-infected patients with suppressed virus replication (86, 88,
89). These abnormal NK cells express KIRs,
and their defective lytic capability has been attributed in part to elevated expression of inhibitory KIR2DL2/2DL3 receptors that bind
to HLA-C (88).
Because of the nature of NK cell regulation
and HIV infection, the effect of inhibitory and
www.annualreviews.org • HLA/KIR Restraint of HIV

301

IY29CH12-Carrington

ARI

Linkage
disequilibrium (LD):
nonrandom
association between
alleles of different
linked loci
Balancing selection:
natural selection that
acts to maintain
multiple alleles of a
gene either by favoring
heterozygotes
(overdominance) or by
favoring rare alleles
(frequency dependent
selection)

4 February 2011

16:54

activating signaling is complex. Although NK
cell activation may result in the killing of infected cells, inhibitory signaling is required for
NK cell education (13) and may also diminish
immune activation, a characteristic of disease
progression (16).

HLA POLYMORPHISM
AND HIV/AIDS
The primary inﬂuence of variation within the
HLA class I loci on the level of viral load and
AIDS progression relative to all other single
human genetic variants has now been set in
stone by the several GWAS published to date
(90–93). The most signiﬁcant variants identiﬁed include a single nucleotide polymorphism
(SNP) in the HCP5 gene, which is in virtually perfect linkage disequilibrium (LD) with
HLA-B∗ 5701 in Caucasians (90–92, 94), two
variants located 35 kb upstream of the HLA-C
locus (90–92, 94), and an intronic variant in the
HLA-B gene linked to HLA-B∗ 5703 in African
Americans (93). The genome-wide signiﬁcance
of SNPs linked to B∗ 57 alleles supports previous genetic and functional data on the importance of the HLA-B locus in HIV pathogenesis, particularly strong protection conferred by
B∗ 57 alleles. These studies also provide novel
evidence for a principal role for the HLA-C locus in HIV disease control. Of note, no class II
associations were evident from the GWAS, and
the HLA-A locus does not show a clear effect
(91).
Individual HLA alleles and alleles grouped
together based on a given hypothesis have been
associated with HIV outcomes. One of the most
interesting recent developments in this regard
is the move to investigate effects of noncoding
regions, which seem to contain riches that are
only beginning to be unearthed.

HLA Heterozygote and/or
Rare Allele Advantage?
Properties of the MHC locus have set it apart
from other genes. HLA genes contain many
sequence variants, similar to microsatellites,
302
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immunoglobulin (Ig) genes, and T cell receptors (TCR), but unlike microsatellites, HLA
genes do not have high mutation rates (95), nor
are there specialized mechanisms for somatic
diversiﬁcation as are found with Ig and TCR
genes. In addition, the polymorphic variation
at the MHC class I and II loci is older than
that in any other known locus, as determined
by both the time needed to accumulate the observed allelic divergencies and the observation
that allelic variants similar to those of humans
are found in apes. In multiple species, the class
I and II allelic frequencies are more evenly distributed than expected by chance, with an excess
of intermediate frequency alleles. These diverse
and peculiar properties of class I and II genes
are well explained by the existence of balancing selection acting on these loci. The primary
function of these MHC molecules is to present
foreign antigens to elicit T cell responses, so
a pathogen-driven form of balancing selection
is often invoked. For many reasons, however,
commensal organisms of the gut and other tissues may be a more likely driving force of MHC
balancing selection because they have a long
symbiotic relationship with their host but are
occasionally pathogenic and need to be constantly kept in check (96).
Balancing selection itself can occur in one
of two forms, either heterozygote advantage
(overdominant selection) or rare allele advantage (frequency-dependent selection). Heterozygote advantage contends that in general,
individuals who are heterozygous at the HLA
locus will present a broader repertoire of antigenic peptides to T cells than will homozygotes, challenging the pathogen to escape from
a greater variety of CTL responses. Rare allele advantage is based on the premise that the
most frequent form of a pathogen circulating
in a given population is more likely to have escaped from common HLA alleles, making the
low frequency allotypes advantageous for the
host.
The relative contributions of each of these
models have been subject to debate (97). HIV
epidemiological data have been applied to test
both models. Data supporting a heterozygote
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advantage against HIV showed an increasingly
protective effect, in terms of disease progression, with greater numbers of distinct HLA class
I alleles (98, 99). Recent work on cynomolgus
monkeys demonstrated lower chronic SIV viral loads by nearly two logs in class I heterozygous as opposed to homozygous animals (100).
Based on viral sequences, heterozygous monkeys appear to exert greater overall CD8 T cell
pressure on the virus compared with that in homozygous animals. The breadth of Gag-speciﬁc
CD8 T cell responses to HIV correlates with
lower viral load (54, 55), which may be due in
part to a greater number of distinct class I alleles
in heterozygous patients.
In support of a rare allele advantage, investigators have demonstrated a positive correlation
between viral load and the frequency of HLA
class I supertypes (101). As the model suggests,
such a correlation may be due to viral adaptation at a population level. Indeed, a recent
study in nine cohorts representing ﬁve continents demonstrated a strong positive correlation between epitope mutations and frequencies of restricting HLA class I alleles (47).
Based on HIV genetic epidemiologic data,
it is difﬁcult to clearly distinguish heterozygous
advantage from rare allele advantage because
low frequency alleles are much more likely to
occur in the heterozygous form. It is plausible
that both heterozygote advantage and rare allele
advantage apply to HIV-infected individuals.
Despite all theoretical support of evolutionary
models, however, HIV is unlikely to have any
permanent effect on HLA allelic frequency distributions. But the effect of HLA on HIV evolution is evident in a geographic-speciﬁc sense.

HLA-B Locus: The Queen Bee of HIV
Host Genetics
The HLA-B locus is the most polymorphic of
all the HLA loci (102). Perhaps related to its extensive diversity, it also shows the strongest and
most consistent genetic effects on outcomes of
HIV infection relative to the other HLA class I
and class II genes (103). Functional data from
a large study of clade C patients showed that

most CD8 T cell responses to HIV were HLAB restricted and that variation in viral load was
predominantly associated with variation at the
HLA-B locus (104), nicely correlating the genetic data with functional analysis and emphasizing the importance of HLA-B polymorphism
in determining the outcome of HIV infection.
The HLA-B∗ 57 allele tops all others in terms
of its effect on HIV, and this effect is protective both in terms of viral load control and delayed progression to AIDS (104–108). HLAB∗ 57 carriers are overrepresented among EC
(105, 108) and present symptoms of acute HIV1 infection less frequently compared with noncarriers (109). The exclusive status of B∗ 57
in HIV pathogenesis relative to SNPs located
throughout the rest of the genome is being repeatedly observed with each additional GWAS
report (90–94). An early genetic effect of B∗ 57
after HIV infection was originally indicated by
survival analyses, where B∗ 57 protection was
most apparent for time to CD4<200 (the earliest outcome available for survival analysis in our
cohorts), as opposed to an AIDS-deﬁning illness or death (106). The effect of B∗ 57 has now
been shown for set point viral load (92), an outcome that occurs much earlier than CD4<200.
Several factors contributing to the mechanism of B∗ 57 protection have been suggested.
B∗ 57 restricts three or four immunodominant
epitopes located in conserved regions of Gag,
and escape mutations within these targeted epitopes are commonly observed in viruses isolated
from B∗ 57-positive individuals (27, 36, 46, 110).
Reduced viral ﬁtness of the escape variants, veriﬁed by both in vitro assays and in vivo reversions (27–29, 36), may explain in part the B∗ 57
protective role. A recent study suggests a dual
mechanism for B∗ 57-related viral control involving both viral ﬁtness loss and induction of
CD8 T cell response against escaped epitopes
(30).
An important feature of B∗ 57 is its immunodominance in acute CD8 T cell responses, which appears to be greater than
that of any other HLA allotype, with the
most frequently targeted epitope being Gag
TW10 (111). Mathematical models of T cell
www.annualreviews.org • HLA/KIR Restraint of HIV

303

IY29CH12-Carrington

ARI

4 February 2011

16:54

selection in the thymus support the concept of
B∗ 57 immunodominance by predicting a relatively large pool of B∗ 57-restricted naive T cells
speciﬁc for HIV compared with cells restricted
by other class I allotypes (112). These models
also implicate greater cross-reactivity of B∗ 57restricted CD8 T cells to mutating epitopes.
Dominant, cross-reactive targeting of Gag epitopes by B∗ 57-restricted CD8 T cells may be
important in control of viral replication because
Gag can be presented by infected cells early
postinfection, even before viral integration and
protein synthesis (57). Targeting multiple Gag
epitopes by B∗ 57-restricted CTLs is additionally advantageous to the host because it complicates viral escape from the total CD8 response.
HLA-B∗ 27 also provides protection in terms
of viral control and AIDS progression (106–
108, 113, 114). The mechanism of B∗ 27 protection may be somewhat similar to B∗ 57, as
it involves induction of an immunodominant
CD8 response against a highly conserved Gag
epitope (40, 111, 115), coming in second after B∗ 57 in the hierarchy of immunodominance
during acute phase (111). Despite certain similarities to B∗ 57, B∗ 27 protection has distinct
features. Unlike the B∗ 57-restricted CD8 response, which targets up to four Gag epitopes,
B∗ 27 restriction is focused on a single epitope, KK10. Under B∗ 27-restricted pressure,
the virus undergoes a complex pattern of mutations that result eventually in a fully escaped
virus with wild-type levels of replicative capacity (116). Development of this escape proﬁle results in rapid disease progression (40, 115, 117).
The escape is typically conferred by three mutations, S173A/R264K/L268M (116). Delay in
the development of this variant is thought to be
due to impaired replicative capacity of viruses
that bear the individual mutations S173A or
R264K (116). B∗ 27 escape mutations seem to
be stable upon transmission to B∗ 27-negative
subjects, in contrast to B∗ 57 escape mutations,
which often revert back in HLA-mismatched
individuals (118). The B∗ 27 peptide-binding
speciﬁcity is shared, remarkably, with MamuB∗ 08, a macaque MHC class I allotype that
confers protection in SIV infection (119). Most
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Mamu-B∗ 08-restricted SIV epitopes and B∗ 27restricted HIV-1 epitopes possess a dibasic motif at the N terminus (RK or KK), a feature
that makes these peptides resistant to peptidases
and therefore more stable in the cytosol. Unlike
B∗ 27, however, protection conferred by MamuB∗ 08 does not involve immunodominant targeting of a Gag epitope and delayed viral escape:
The Mamu-B∗ 08-restricted YL9 epitope (analog of HIV-1 KK10) is rarely targeted in SIVinfected Mamu-B∗ 08-positive animals (119).
HLA-B∗ 35 alleles associate with susceptibility to AIDS across multiple studies (98,
120–122). B∗ 35-restricted CD8 T cells rarely
recognize Gag in primary infection (123). Gao
et al. (3) identiﬁed a subset of alleles, termed
B∗ 35-Px, that associate most strongly with
the susceptible effect. The B∗ 35-Px allotypes
(B∗ 3502, B∗ 3503, B∗ 3504, B∗ 5301) prefer to
bind peptides with small hydrophobic residues
at position 9 (2, 124), as opposed to the B∗ 35PY allotypes (B∗ 3501 and B∗ 3508), which favor
binding peptides with tyrosine at the same position (125, 126). Perhaps B∗ 35-Px presents peptides that are distinct from and less protective
than those presented by B35-PY (for example,
PY9 Gag epitope), although in vitro data do not
support clear differences in peptide-binding
speciﬁcity between B∗ 35-Px and B∗ 35-PY
(123, 127). Still, some disparity in correlations
of CD8 T cell targeting of Gag and viral loads
were detected between the two B∗ 35 groups
(128). A novel view of the B∗ 35 susceptibility
mechanism involving dendritic cells (DCs) was
suggested recently (127) based on the observation that B∗ 35-Px binds to the Ig-like transcript
4 (ILT4), an inhibitory receptor expressed on
DCs, with greater afﬁnity than does B∗ 35-PY
in the presence of the same HIV-1 peptides.
This may result in more prominent DC
dysfunction in B∗ 35-Px-positive individuals,
thereby accelerating disease progression (127).

HLA-C: The Dark Horse
of HIV Host Genetics
A primary role for HLA-C as a CTL restriction
factor has been questioned because of its limited
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polymorphism and its low level of cell surface
expression compared with its HLA-A and -B
counterparts (129). It is now known that every
HLA-C allotype is a ligand for inhibitory KIR
and that virtually every individual possesses the
KIR genes that encode receptors for HLA-C
(130), implicating this locus as the most
important in terms of KIR regulation of NK
cell activity. Indeed, an effect of certain HLA-C
genotypes in combination with KIR2DL3 was
implicated with HCV clearance previously
(131). However, in contrast to HLA-B alleles,
neither individual HLA-C alleles nor combinations of HLA-C groups with KIR have shown a
consistent effect with HIV pathogenesis (apart
from those that are more readily explained
by LD with HLA-B alleles). HLA-C is the
only classical HLA class I molecule that is not
downregulated by HIV Nef (82), which further
points to a functional distinction of this locus
compared with HLA-A and -B. Recently, a
grouping of HLA-C alleles marked by a SNP
upstream of the locus was shown to have the
second most signiﬁcant effect on HIV viral
load genome-wide, tapping into a previously
undiscovered role for HLA-C in control of the
virus.
This variant, located 35 kb upstream of
the HLA-C gene (-35C/T ), was identiﬁed
as the second strongest hit associated with
control of HIV-1 viral load in European

Americans (92), and this region was implicated
again in subsequent GWAS studies (90, 91,
94). It was suggested, based on B cell line
mRNA data, that that the effect of the -35
variant may be due to differences in HLA-C
gene expression (92, 132). To identify a potential mechanism for the protection conferred
by this variant, we examined HLA-C expression on CD3 T lymphocytes of normal donors
using an HLA-C-speciﬁc monoclonal antibody
and showed that the -35CC genotype associates with signiﬁcantly higher HLA-C cell surface expression than does the -35TT genotype
(Figure 4a). The -35CC genotype also associates with better control of viral load compared
with -35TT in our ART naive seroconverter cohorts (Figure 4b). Thus, high-expression HLAC alleles are in LD with the protective -35C
variant, whereas low-expression alleles are in
LD with the susceptible -35T allele (133). It
is not clear why high expression of HLA-C
would be protective against HIV, but one obvious possibility is that higher HLA-C expression
may enhance antigen presentation to CTLs.
Additionally, high HLA-C expression may result in more effective education of NK cells
during their maturation process through better engagement of inhibitory NK receptors to
HLA-C ligands, ultimately leading to stronger
NK cell responses to HIV-infected target
cells.
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Figure 4
The -35 genotype (TT, CT, or CC) correlates with surface HLA-C expression (a) and mean log viral load (b).
HLA-C expression was detected on CD3+ T lymphocytes of normal individuals by ﬂow cytometry using the
DT9 monoclonal antibody and compared between pairs of genotypes. The association of the -35 genotypes
with mean log viral load was analyzed in a cohort of 923 HIV-1-infected patients. The ﬁgure is based on data
published previously (133).
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Data now show that high levels of HLAC expression indeed exert selection pressure
on the virus, as HIV-1 Nef variants from
-35CC individuals have an increased ability to
impair both class II antigen presentation and
helper T cell function to counteract an HLAC-mediated immune response (134). In another
recent study of individuals with chronic HIV1 infection, HLA-C-restricted CTL activity
accounted for 54% of the total HIV-speciﬁc
peptide response, and these CTLs had similar phenotypic characteristics to HLA-A- and
-B-restricted CD8 T cells (135). Even though
differences between high- and low-expressing
HLA-C-speciﬁc CTL responses were not investigated, these results are intriguing in the
light of the -35 ﬁndings. Thus, HLA-C is now
a focal consideration in host genetics against
HIV and may be an emerging contender for
HIV vaccine design.

HLA Class II
No strong consistent genetic epidemiological
data indicate that variation at the HLA class II
loci associates differentially with HIV/AIDS
outcomes, although several reports suggest
this possibility. Potential involvement of
HLA-DRB and -DQB loci in the risk of
infection among African populations have
been reported, with some consistent protective
effect of HLA-DRB1∗ 01 and a susceptible effect
of DRB1∗ 1503 (136–138). The DRB1∗ 1301/2DQB1∗ 06 haplotype was associated with viral
control after ART interruption, potentially
through efﬁcient presentation of a Gag peptide
that partially overlaps with the KK10 peptide
presented by B∗ 27 (79). DRB1∗ 1301 carriers
were also less likely to transmit virus to their
seronegative partners, although the allele
had no apparent effect on viral load (138).
DRB1∗ 1303 demonstrates a protective effect
on viral load in chronically infected individuals
in a South African cohort as well as in a U.S.
cohort, but DRB1∗ 1301/02 does not (B. Julg,
personal communication).
Speciﬁc combinations of class I and class II
alleles may interact synergistically, as suggested
306

Bashirova

·

Thomas

·

Carrington

in a study where Mamu-B∗ 17-positive rhesus monkeys bearing Mamu-DRB1∗ 1003 and DRB1∗ 0306 controlled SIV signiﬁcantly better
than Mamu-B∗ 17 carriers that did not express
these class II alleles (139). Testing combinations of class I and class II alleles for effects
in HIV/AIDS is worth pursuing, but the study
cohorts would have to be large to have enough
power to be conclusive.

KIR POLYMORPHISM
IN HIV/AIDS
Both presence/absence and allelic variation at
some of the KIR genes have been implicated in
risk of various human diseases and disease outcomes (140). Owing to the functional relationship between HLA class I and KIR loci, an analytical approach that takes into account relevant
KIR and HLA genotype combinations has been
applied to disease association studies. Strong
synergistic effects of KIR and HLA genes/alleles
observed in hepatitis C (131) and HIV cohorts
(141, 142) emphasize the importance of KIRHLA interactions in regulating NK cell activity
during viral infections.

KIR3DL1/S1 and HLA-B Bw4
Synergism in AIDS Outcomes
Analysis of AIDS progression in ART naive
seroconverters indicated a protective effect of
a compound genotype consisting of KIR3DS1
and Bw4-80I (141) (Figure 5a). This ﬁnding
was the ﬁrst to describe an epistatic interaction
between KIR and HLA in disease association
and indicated the possibility that activating
KIR may have biological signiﬁcance in viral
infection. The KIR3DS1/HLA-B Bw4-80I compound genotype was further shown to correlate
with lower viral load and protection from opportunistic infections (143). Thus, the genetic
data suggested that KIR3DS1 may bind HLAB Bw4-80I ligands on HIV-infected target cells
in vivo and that this interaction may delay AIDS
progression. In good support of this, Alter et al.
(144) demonstrated that NK cells expressing
KIR3DS1 strongly inhibit HIV replication
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Figure 5
The effect of KIR3DS1 and HLA-B Bw4-80I on HIV infection. (a) Kaplan-Meier survival analysis comparing individuals homozygous
for HLA-B Bw6 and individuals with the KIR3DS1/Bw4-80I compound genotype in HIV seroconverters as described in Reference 142.
(b) Inhibition of viral replication by NK cells derived from subjects expressing both KIR3DS1 and Bw4-80I, HLA-B Bw4 and no
KIR3DS1, KIR3DS1 and no HLA-B Bw4, and neither KIR3DS1 nor HLA-B Bw4. Inhibition of viral replication in the ﬁrst groups is
signiﬁcantly higher than in any other group (p < 0.001). The data were presented in Reference 144.

in target cells expressing HLA-B Bw4-80I
compared with KIR3DS1-negative cells
(Figure 5b). However, the synergistic protective effect of KIR3DS1 and HLA-B Bw4-80I
was not seen in two other studies (145, 146),
which may have to do with distinct clinical
characteristics of the cohorts, the speciﬁc
disease outcomes tested, and/or differences
in analytical methods. But failure to detect
any direct binding of KIR3DS1 to HLA-B
Bw4-80I (147, 148) is puzzling and leaves
open the possibility that other variants in
the MHC and KIR loci, which are tracked
by KIR3DS1 and/or Bw4-80I through LD,
account directly for the protective effect against
HIV. Reconciling all these observations must
take into account the evidence for selection
pressure to maintain KIR3DS1 (149) as well as
population genetic data showing a signiﬁcant
inverse correlation in the frequencies of
KIR3DS1 and HLA-B Bw4-80I across world
populations (Figure 6) (150). No other known
or suspected receptor/ligand combinations of
KIR and HLA showed a signiﬁcant correlation
in the last study, although an association
between KIR2D and a group of HLA-C alleles
was observed in a subsequent study (151). The
data suggest pressure to maintain a certain

low level of the KIR3DS1/HLA-B Bw4-80I
combination, which may actually increase risk
of some other disease(s).
The effect of KIR3DS1 in combination with
HLA-B Bw4-80I implied that activation of NK
cells is beneﬁcial in HIV disease. Surprisingly,
analysis of inhibitory KIR3DL1 alleles with
HLA-B Bw4-80I, suggested that engagement
of this receptor is also protective against
HIV. The KIR3DL1 allotypes can be divided
into those with high expression and high
inhibitory capacity, KIR3DL1∗ h/y, and those
with lower expression and lower inhibitory
activity, KIR3DL1∗ l/x (142). Remarkably, the
KIR3DL1∗ h/y + HLA-B Bw4-80I compound
genotype demonstrated signiﬁcant protection
from AIDS progression in the same seroconverter cohorts that showed a protective effect
of the KIR3DS1/HLA-B Bw4-80I genotype,
and it was also associated with lower mean
viral loads (141). These data suggest that
efﬁcient engagement of both activating and
inhibitory KIR is beneﬁcial for the host in viral
infection and point to the central signiﬁcance
of the HLA-B locus not only from an acquired
immune response perspective but also in terms
of innate immunity. The yin-yang situation
in which both activating and inhibitory KIR
www.annualreviews.org • HLA/KIR Restraint of HIV
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Figure 6
KIR3DS1 and HLA-B Bw4-80I frequencies across populations. Populations are ordered by region based on increasing distance from
East Africa. Frequencies of KIR3DS1 increase with the distance from Africa, whereas frequencies of HLA-B Bw4-80I have the opposite
trend. As a result, the frequency of the compound KIR3DS1/Bw4-80I genotype is maintained at an approximately similar low level
across populations. The ﬁgure is modiﬁed from Reference 150.

alleles confer protection may boil down to protection through NK cell activation. Protection
conferred by an activating receptor (KIR3DS1)
is intuitively straightforward. Protection by
highly inhibitory allotypes (KIR3DL1∗ h/y)
may be attributed to more potent tuning of the
high-expressing KIR3DL1-positive NK cells
during their maturation process, eventually
resulting in stronger activation of those NK
cells when their ligand is downregulated (as
HLA-B is by HIV Nef ).
Notably, the two most protective HLA-B
alleles, B∗ 57 and B∗ 27, belong to the Bw4-80I
and Bw4-80T groups, respectively. As is true
for all Bw4 alleles, the effects of these protective
alleles on HIV infection can be mediated by
both CD8 T cell and NK cell activity. Indeed,
individuals carrying both KIR3DL1∗ h/y and
B∗ 57 alleles exhibit the strongest genetic protection both in terms of AIDS progression and
viral load in our cohorts (142). Involvement
of NK cells in this protection is supported by
recent data indicating high functional potential
of NK cells isolated from individuals expressing
KIR3DL1∗ h/y and B∗ 57, which might be due
to the efﬁcient education of these NK cells
(152). B∗ 27, on the other hand, showed greater
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protection in the presence of KIR3DL1∗ l/x
than in the presence of KIR3DL1∗ h/y
(142), which might indicate speciﬁcity of
low-expression KIR3DL1 allotypes for
B∗ 27.

KIR Genes in Protection
From HIV Infection
Protection from HIV infection in the absence
of vaccination is likely to depend on a rapid and
efﬁcient innate immune response characteristic of NK cells. Increased NK cell activity was
detected in highly exposed uninfected intravenous drug users compared with HIV-infected
patients and healthy individuals (153). Within
the same cohort, the KIR3DS1/3DL1 transcript
ratio was higher among protected individuals
(154). The possibility that KIR3DS1 may help
protect from HIV infection was supported by
a genetic association study that demonstrated a
higher frequency of the KIR3DS1 homozygous
genotype among exposed HIV-1-negative individuals (155). In a subset of the same cohort,
the KIR3DL1∗ h/y + HLA-B Bw4 80I genotype was also associated with reduced risk of
infection (156), consistent with the effect on
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viral load and disease progression (142). Notably, however, studies of genetic variants that
have incomplete penetrance on risk of infection (unlike homozygosity for CCR532, which
provides virtually complete protection from infection) are subject to several problems: poor
statistical power due to limited sample sizes,
difﬁculty in identifying individuals who have
clearly been exposed repeatedly and remain uninfected, and difﬁculty in identifying a control
group of HIV-infected individuals where selection bias is not an issue. The latter point is subtle
and important. In most HIV cohorts, there is
a strong possibility that rapid progressors are
missing due to frailty bias, thereby artiﬁcially
increasing the frequency of variants associated
with nonprogression and decreasing the frequency of variants associated with rapid progression. Such cohorts do not serve as appropriate controls in studies of exposed uninfected
individuals.

CONCLUDING REMARKS
The outcome of HIV infection in humans
is deﬁned by complex interactions between a

Table 1

polymorphic virus and a polymorphic host immune system. Discriminating between cause
and effect of an observed immune response
to the virus can be problematic when studying these interactions at a given time point.
The beauty of genetic epidemiological studies
is that they can provide an in vivo population
view of factors that affect the host response to
the virus differentially across humans, giving
meaning in some cases to in vitro functional
data. There is a give-and-take situation between
genetic and functional studies, where reliable
genetic studies depend on conﬁrmation from
functional studies. A prime example of mutual
support between genetic and functional data in
HIV disease involves the HLA loci and their
impact on effector cell activity (Table 1). Several groups are now probing combined effects
of variation at the HLA and KIR loci through
functional assays as a follow-up to some genetic
studies, which is important because certain innate immune responses may prevent infection
in a natural history setting, and they also embody the critical early control of the virus.
HIV presents an extreme challenge to
the human immune system. The virus has

HLA class I associations with HIV-1 infection outcomes
Effect

GWAS
significance

Heterozygote advantage/rare allele
advantage at HLA class I

Protection

Not applicable

Broader CTL response (98, 100); viral escape from
common alleles (47, 101)

B∗ 57

Protection

Yes

Immunodominant targeting of multiple conserved Gag
epitopes and reduced viral ﬁtness of escapes (27–30,
36); cross-reactive nature of epitope restriction (30,
112); interaction with KIR3DL1/3DS1 (141, 142, 152)

B∗ 27

Protection

No

Immunodominant targeting of a conserved Gag epitope
and delayed complex escape (40, 111, 115, 116);
resistance of epitopes to peptidases (119); interaction
with KIR3DL1 (142)

B∗ 35-Px

Susceptibility

No

Peptide binding speciﬁcity (3); ILT4-mediated
dysfunction of DCs (127)

-35CC; HLA-C

Protection

Yes

Efﬁcient CTL or NK cell activity due to high-level
expression of linked HLA-C alleles (133)

KIR3DS1+HLA-B Bw4 80I

Protection

Not applicable

Elevated NK cell cytotoxicity via potential engagement
of KIR3DS1 (84, 141, 144)

KIR3DL1∗ h/y+HLA-B Bw4 80I

Protection

Not applicable

Elevated NK cell cytotoxicity due to efﬁcient NK cell
education (142, 152)

Genotype

Suggested mechanisms
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remarkable genomic ﬂexibility, evolving into
the ﬁttest form as dictated by the speciﬁc immune system of each individual human host that
it infects. The immune systems of some individuals can back the virus into a corner and hold
it there, but these people are rare. The precise

mechanism(s) for how B∗ 57 and other immunogenetic variants are capable of forcing the virus
to evolve into a form that the host can manage
indeﬁnitely needs to be delineated so that this
information can be taken into account in the
generation of logical vaccines.
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Erratum:

Figure 4b was changed from the original such that the y-axis label runs from 0 to 8, rather than
from 0 to 70.
This erratum was posted online on May 6, 2011.

